In addition, studies have shown that PTPN2 deficiency might enhance the therapeutic effect of CAR-T cells in malignant tumors, therefore, we can combine PTPN2 small molecule inhibitors with immunotherapy drugs to obtain a better therapeutic effect on tumors. Here, PTPN2 is linked to cancer.